Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Methyllycaconitine (MLA) is an antagonist of α7-containing neuronal nicotinic acetylcholine receptors (nAChRs; Ki = 1.4 nM).1,2 It is less effective at other nAChRs.3,4 MLA is used to selectively evaluate the role of α7-containing nAChRs in signaling pathways.5,6
WARNING This product is not for human or veterinary use.
1. A positive allosteric modulator of α7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia. Br. J. Pharmacol. 169(8), 1862-1878 (2013).
2. Methyllycaconitine: A selective probe for neuronal α-
3. Characterization of human α4β2-
4. Heterologous expression of human α6β4β3α5 nicotinic acetylcholine receptors: Binding properties consistent with their natural expression require quaternary subunit assembly including the α5 subunit. J. Pharm. Exp. Ther. 312(2), 619-626 (2005).
5. Activation of α7 nicotinic acetylcholine receptor decreases on-
6. Alpha7 nicotinic acetylcholine receptor is required for amyloid pathology in brain endothelial cells induced by Glycoprotein 120, methamphetamine and nicotine. Sci. Rep. 7, 40467 (2017).